CD274 and neoplasm: Nine out of 25 patients with human non-small cell lung cancer (NSCLC), melanoma, or renal cell cancer with ≥ 5% of PD-L1 positive tumor cells had an objective response rate of 36%, while the remainder (PD-L1 < 5%) had no objective response [10].